- Home
- GLXG vs CLRB Comparison
GLXG vs CLRB Comparison
Compare GLXG & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLXG
- CLRB
- Stock Information
- Founded
- GLXG 2013
- CLRB 2002
- Country
- GLXG Hong Kong
- CLRB United States
- Employees
- GLXG N/A
- CLRB N/A
- Industry
- GLXG
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- GLXG
- CLRB Health Care
- Exchange
- GLXG NYSE
- CLRB Nasdaq
- Market Cap
- GLXG 11.1M
- CLRB 12.5M
- IPO Year
- GLXG 2024
- CLRB N/A
- Fundamental
- Price
- GLXG $0.55
- CLRB $0.36
- Analyst Decision
- GLXG
- CLRB Hold
- Analyst Count
- GLXG 0
- CLRB 2
- Target Price
- GLXG N/A
- CLRB N/A
- AVG Volume (30 Days)
- GLXG 73.0K
- CLRB 34.3M
- Earning Date
- GLXG 06-17-2025
- CLRB 05-13-2025
- Dividend Yield
- GLXG N/A
- CLRB N/A
- EPS Growth
- GLXG N/A
- CLRB N/A
- EPS
- GLXG N/A
- CLRB N/A
- Revenue
- GLXG $3,711,233.00
- CLRB N/A
- Revenue This Year
- GLXG N/A
- CLRB N/A
- Revenue Next Year
- GLXG N/A
- CLRB N/A
- P/E Ratio
- GLXG N/A
- CLRB N/A
- Revenue Growth
- GLXG N/A
- CLRB N/A
- 52 Week Low
- GLXG $0.52
- CLRB $0.22
- 52 Week High
- GLXG $16.93
- CLRB $3.42
- Technical
- Relative Strength Index (RSI)
- GLXG N/A
- CLRB 61.13
- Support Level
- GLXG N/A
- CLRB $0.23
- Resistance Level
- GLXG N/A
- CLRB $0.69
- Average True Range (ATR)
- GLXG 0.00
- CLRB 0.05
- MACD
- GLXG 0.00
- CLRB 0.02
- Stochastic Oscillator
- GLXG 0.00
- CLRB 26.84
About GLXG GALAXY PAYROLL GROUP LTD
Galaxy Payroll Group Ltd provides payroll outsourcing, employment, consultancy, and market research services based in Hong Kong. Its client base includes retail, trading, industrial, IT, financial, and professional services industries. Geographically, the company derives maximum revenue from its clients in the People's Republic of China and the rest from Hong Kong, Macau, Taiwan, Japan, Thailand, Singapore, and other countries.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.